TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Mobility Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years admitted to one of the five hospital wards of the Birmingham VA Medical Center (VAMC) for any medical illness, e.g.:~  * Pneumonia~ * Heart failure~ * Chronic obstructive pulmonary disease (COPD) exacerbation~ * Or other medical (versus surgical) indication for hospitalization~* Patients will be recruited within 48 hours of hospitalization, followed throughout their hospitalization and for one year after hospital discharge.~Exclusion Criteria:~* Patients admitted for brief observation will be excluded, e.g.:~  * 23-hour observation for possible myocardial infarction~ * Additional exclusion criteria will include:~ * Inability to walk across a small room 2 weeks prior to admission~ * Inability to walk safely with assistance, based on a strength and balance screen (see Training of Walkers, below for details)~ * Having a pulmonary embolus, unstable angina or other medical diagnosis deemed by the primary physician to be a contraindication to walking~ * Being on hospice or comfort care~ * Being in a semi-private room with another currently enrolled participant~ * Non-English speaking, blind, or deaf

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive (Type: EXPERIMENTAL): MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
- Friendly visit (Type: PLACEBO_COMPARATOR): UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Diagnosis and Criteria for Inclusion:~* A participant must have been at least 12 years of age, of either sex, and of any race, with a diagnosis of persistent asthma or COPD of at least 12 months.~* A participant must have been able to demonstrate correct use of an MDI without a counter at the Screening Visit.~* A participant must have demonstrated at least 90% compliance with completion of the e-diary, use of the counterstrip, and use of the study medication over the 2-week Screening Period.~Exclusion Criteria:~* Participants with a serious uncontrolled medical disorder, which in the judgment of the investigator, could have interfered with the study, or required treatment which might interfere with the study.~* Participants who in the judgment of the investigator and/or sponsor had a significant recent or current, repetitive strain injury (RSI) that may have impacted their ability to effectively participate in the full duration of the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MF/F MDI 100/10 mcg BID with dose counter (Type: EXPERIMENTAL): MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~patients diagnosed with essential hypertension~Exclusion Criteria:~patients who took Micardis Plus before participating in this PMS study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form prior to any study-mandated procedure.~* Male and female subjects aged from 18 to 75 years (inclusive),~* Subjects with stable pulmonary arterial hypertension (PAH) defined as WHO Functional Class I-III at Visit 1 and Visit 2, and no change (i.e., introduction or dose change) in PAH-specific medication (i.e., ERA, PDE-5 inhibitor or sGC stimulator) and diuretics in the last 28 days prior to Visit 2.~* Subjects currently treated with Uptravi® at a stable dose (i.e. unchanged dose) for at least 28 days before Visit 2.~* Women of childbearing potential must have a negative pregnancy test at Visit 1 (screening) and Visit 2.~Exclusion Criteria:~* Pregnant, planning to become pregnant or lactating.~* Known and documented moderate or severe hepatic impairment.~* Subjects having received gemfibrozil at any time since initiation of Uptravi®.~* Treatment with any prostacyclin and prostacyclin analogs within 28 days prior to Visit 1.~* SBP \< 90 mmHg at Visit 1 or at Visit 2.~* Known or suspected uncontrolled hyperthyroidism.~* Severe renal failure and ongoing or planned dialysis.~* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.~* Known concomitant life-threatening disease with a life expectancy \< 12 months.~* Treatment with another investigational treatment within 3 months of Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Selexipag (Type: EXPERIMENTAL): Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age~* Patient's heart rate meets at least one of the following:~  * Patient has a sinus rate ≤ 50 OR a junctional escape rhythm no faster than 50~ * Patient has a history of exercise intolerance~* Patient complains of general fatigue, shortness of breath, shortness of breath with exertion, syncope, light headed dizziness, palpitations, lethargy, dyspnea OR malaise within the last 30 days that are not related to other discovered causes (such as untreated hypothyroidism or anemia).~* Patient (or patient's legally authorized representative) is willing and able to sign and date written Patient Consent Form/Patient Data Release Consent~Exclusion Criteria:~* Patient has type II 2nd degree AV block, High degree AV block (2:1, 3:1, 4:1 etc.) or 3rd degree AV block~* Patient has recent history of blood loss~* Patient has a medical history leading to suspicion of neurological disorder~* Patient has a history of Chronic Atrial Fibrillation~* Patient is enrolled or planning to participate in a concurrent drug and/or device study at any time during the course of this clinical study without documented pre-approval from the Medtronic study manager~* Patient is not expected to survive for 12 months~* Patient is anticipated to be unwilling or unable to comply with the clinical investigation plan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: None): Control
- Phase II (Type: None): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A 5th grade student in one of the recruited schools~* Student speaks English as a first or second language~* Passive parental consent to participate~Exclusion Criteria:~* Special needs students identified by the classroom teacher as a student who would not understand the questionnaire or the program~* Teacher indicates that they cannot comprehend English.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intervention: Click City Tobacco Prevention Program (Type: EXPERIMENTAL): Participation consisted of a baseline assessment one-week prior to starting the program, and a follow-up assessment one-week following completion of the program. The expectation was that students complete two lessons a week of the computer-based program over a four-week period.
- Control: Usual Tobacco Prevention Curriculum (Type: EXPERIMENTAL): Students in control schools completed the baseline and follow-up assessments during the same week as students in their yoked intervention school. The expectation was that students would participate in the standard tobacco curriculum over this period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the pancreas~  * Patients with clinical 'high probability' of pancreatic cancer and biopsy suggestive but not diagnostic of pancreatic cancer may be eligible based on review by the principal investigator~* Measurable or evaluable disease~* No clinical evidence of active venous thromboembolism~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 60-100% OR WHO PS 0-2~* Life expectancy \> 12 weeks~* Absolute neutrophil count \> 2,000/mm³~* WBC \> 3,000/mm³~* Platelet count \> 100,000/mm³~* Creatinine clearance \> 50 mL/min~* INR ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin \< 1.5 times ULN (stent allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No cerebrovascular accident within the past 6 months~* No obvious contraindication to anticoagulation, including the following:~  * Bleeding diathesis~ * Active peptic ulcer~ * Ulcerating cancer into duodenum~* No history of other advanced malignancy~* No gross hematuria~* No melaena or gross evidence of gastrointestinal bleeding (other than piles)~* No requirement for a central line~* No other significant medial or psychiatric illness that, in the opinion of the investigator, would preclude study participation~PRIOR CONCURRENT THERAPY:~* No prior gemcitabine hydrochloride-containing treatment~* No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and replacement steroids), or experimental medications~* No other concurrent specific anticancer therapy as a result of disease progression~* No concurrent caval filter device~* No other concurrent anticoagulants for venous thromboembolism or other reasons (e.g., atrial fibrillation)~* No concurrent acetylsalicylic acid (\> 75 mg) as an antiplatelet drug for a preexisting cardiovascular condition~* No concurrent clopidogrel bisulfate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically confirmed carcinoma of unknown primary site~* Progressive disease after treatment with one previous chemotherapy regimen.~* Treatment with one previous immunotherapy or biotherapy regimen.~* No previous treatment with oxaliplatin, capecitabine, or 5-FU.~* Previous treatment with other platinum agents~* Patients must have measurable or evaluable disease~* ECOG Performance Status more than 2~* Adequate bone marrow, liver and kidney function~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* History of treatment of any invasive malignancy within the last 5 years~* Coexistent medical illnesses~* Clinically significant cardiac disease~* Preexisting peripheral neuropathy \> grade 1~* Lack of physical integrity of the upper gastrointestinal tract~* Pre-existing uncontrolled coagulopathy~* Women who are pregnant or lactating~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin/Capecitabine (Type: EXPERIMENTAL): All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Bacterial Vaginosis Combined With Human Lactobacilli

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* were regularly menstruating women, 18 years or older, with normal gynaecological status, not pregnant or breast-feeding and without signs of other genital tract infections.~Exclusion Criteria:~* Exclusion criteria were patients with hormonal IUD without regular menstruation; women infected with Chlamydia trachomatis or with Trichomonas vaginalis, or with a clinical candida infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Lactobacilli (Type: ACTIVE_COMPARATOR): different lactobacilli.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female aged 18-69 years~* diagnosed pathologically as early breast cancer~* with indication for adjuvant chemotherapy and suitable for AC regimen (epirubicin and cyclophosphamide, or pirarubicin and cyclophosphamide, planned chemotherapy with taxanes after AC regimen were allowed)~* received no prior chemotherapy (chemotherapy naïve)~* have Karnofsky performance status ≥ 80,~* baseline hemoglobin ≥90g/L, white blood cell count ≥4.0X10\^9/L,ANC≥2.0X10\^9/L, platelet count ≥100X10\^9~* adequate cardiac, hepatic and renal function~Exclusion Criteria:~* enrolled onto or had not yet completed other investigational drug trials~* allergic to any component of PEG-rhG-CSF injection, or other biological products derived from genetically engineering Escherichia coli;~* pregnant or lactating women;~* previous large volume radiotherapy, or prior bone marrow or stem-cell transplantation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- pegfilgrastim 3mg (Type: EXPERIMENTAL): Pegfilgrastim 3mg per chemotherapy cycle
- pegfilgrastim 6mg (Type: ACTIVE_COMPARATOR): Pegfilgrastim 6mg per chemotherapy cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Presenting for surgical abortion~* Gestational age \<12 weeks~* \< 18 years of age~* Agrees to be randomized~Exclusion criteria:~* Allergy to study medications (lidocaine, fentanyl, midazolam)~* \> 18 years of age~* Fetal demise~* Pre-procedure use of misoprostol~* No means of transportation following procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcutaneous electrical nerve stimulation (TENS) (Type: EXPERIMENTAL): Transcutaneous electrical nerve stimulation (TENS)
- Moderate IV Sedation (Type: ACTIVE_COMPARATOR): Fentanyl, versed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with COPD according to GOLD 2011 who have signed informed consent.~2. Patients with airflow limitation of 30-80% post-bronchodilator FEV1 at run-in.~3. Current or ex-smokers with a smoking history of at least 10 pack years~4. Patients with a mMRC score of at least 2 at run-in.~Exclusion Criteria:~1. Patients contraindicated for muscarinic antagonist agents and beta-2 agonists~2. Patients with a history of malignancy of any organ system, treated or untreated, within the last five years~3. Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention~4. Patients who had a COPD exacerbation within 6 weeks prior to screening.~5. Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.~6. Patients with a history of asthma.~7. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to 40 years of age.~8. Patients with a blood eosinophil count of greater than 600 mm/3 during run-in~9. Patients with concomitant pulmonary disease~10. Patients with a history of certain cardiovascular co-morbid conditions~11. Patients with a diagnosis of alpha-1 anti-trypsin deficiency~12. Patients with active pulmonary tuberculosis~13. Patients in the active phase of a pulmonary rehabilitation programme~14. Other protocol-defined inclusion / exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 dose 1 (Type: EXPERIMENTAL): NVA237 dose 1
- Long-acting beta 2-agonist (LABA) (Type: ACTIVE_COMPARATOR): QAB149

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Adult male and female participants who voluntarily sign the informed consent.~* Fasting lipid results following greater than 12-hour fasting period:~  * Triglycerides level greater than or equal to 150 mg/dL,~ * High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and~ * Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL.~* Participant must agree to utilize adequate birth control methods and adhere to the American Heart Association (AHA) diet.~Exclusion Criteria~* Participants with unstable medical conditions, medical conditions considered inappropriate in a clinical trial, or participants who are taking excluded concomitant medications are not allowed in the study.~* Participants receiving coumarin anticoagulants or systemic cyclosporine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 and Rosuvastatin Calcium (Type: EXPERIMENTAL): ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
- ABT-335 (Type: ACTIVE_COMPARATOR): ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
- Rosuvastatin Calcium (Type: ACTIVE_COMPARATOR): Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete